Actively Recruiting
Study of Neoadjuvant Chemotherapy with Anlotinib and Benmelstobart in Women Aged 18 to 75 With HRHER2- Breast Cancer
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-08-12
35
Participants Needed
3
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying a new treatment approach for women with HRHER2- breast cancer, focusing on combining neoadjuvant chemotherapy with two drugs called Anlotinib and Benmelstobart. This phase 2 trial aims to explore how this combination might allow for less intense chemotherapy while maintaining effectiveness. The main goal is to measure the percentage of patients who achieve a complete response in their breast tissue after treatment, providing insights to improve precision treatment options. The study involves two treatment groups receiving different sequences of chemotherapy drugs combined with Benmelstobart given intravenously every three weeks in cycles, along with oral Anlotinib taken daily before breakfast for two weeks followed by a one-week break. Each treatment cycle lasts 21 days, with a total of three cycles planned. Group A receives Epirubicin and cyclophosphamide first, then nab-paclitaxel, while Group B starts with nab-paclitaxel followed by Epirubicin and cyclophosphamide, both combined with Benmelstobart and Anlotinib. Participants will be monitored closely throughout the treatment and follow-up periods. Researchers will evaluate pathological complete response and residual cancer burden over two years, and also track event-free survival over three years. Assessments include routine lab tests, heart function monitoring, and questionnaires to ensure safety and treatment adherence. The study starts in May 2025 and continues until April 2030, with detailed follow-up to understand long-term outcomes and safety.
CONDITIONS
Brief Title
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Research Team
Z
Zhijun Dai, Professor
Y
Youyi Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here